Literature DB >> 7589024

Effects of daytime administration of zolpidem versus triazolam on memory.

N J Wesensten1, T J Balkin, G L Belenky.   

Abstract

To determine whether zolpidem (an imidazopyridine hypnotic) produces amnestic effects which are similar to those produced by triazolam (a benzodiazepine hypnotic), 70 subjects were administered either triazolam (0.125, 0.25, or 0.5 mg), zolpidem (5, 10, or 15 mg) or placebo, then tested on Simulated Escape, Restricted Reminding, and Paired-Associates memory tests at 1.5 hours post-dosing (i.e., near the time of estimated peak blood concentration for both drugs) and again at 6 hours post-dosing. Triazolam 0.5 mg produced the greatest memory impairment at both test times, and also produced the greatest degree of sedation during intervening daytime naps in a non-sleep-conducive environment. Other doses of triazolam and zolpidem produced less memory impairment, but also failed to significantly enhance sleep. The results are consistent with the view that the amnestic and hypnotic effects of these sleep-inducing medications are functionally coupled.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589024     DOI: 10.1007/BF00192735

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

2.  Performance and sleepiness as a function of frequency and placement of sleep disruption.

Authors:  M H Bonnet
Journal:  Psychophysiology       Date:  1986-05       Impact factor: 4.016

3.  The Walter Reed performance assessment battery.

Authors:  D R Thorne; S G Genser; H C Sing; F W Hegge
Journal:  Neurobehav Toxicol Teratol       Date:  1985 Jul-Aug

4.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

5.  Multiple benzodiazepine receptor localization by light microscopic radiohistochemistry.

Authors:  W S Young; D Niehoff; M J Kuhar; B Beer; A S Lippa
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

6.  Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers.

Authors:  D Warot; G Bensimon; P Danjou; A J Puech
Journal:  Fundam Clin Pharmacol       Date:  1987       Impact factor: 2.748

7.  Acute effects of triazolam and lorazepam on human learning, performance and subject ratings.

Authors:  C R Rush; S T Higgins; W K Bickel; J R Hughes
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

8.  Population study of triazolam pharmacokinetics.

Authors:  H Friedman; D J Greenblatt; E S Burstein; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 9.  The amnesic action of benzodiazepines in man.

Authors:  R G Lister
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

10.  Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more
  8 in total

Review 1.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Zolpidem: a review of its use in the management of insomnia.

Authors:  Tracy Swainston Harrison; Gillian M Keating
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems.

Authors:  Gregory S Parks; Deepti R Warrier; Lars Dittrich; Michael D Schwartz; Jeremiah B Palmerston; Thomas C Neylan; Stephen R Morairty; Thomas S Kilduff
Journal:  Neuropsychopharmacology       Date:  2015-08-20       Impact factor: 7.853

Review 5.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

6.  Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

7.  Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Antoine Tarral; Jean-Marc Gandon
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

8.  The critical role of sleep spindles in hippocampal-dependent memory: a pharmacology study.

Authors:  Sara C Mednick; Elizabeth A McDevitt; James K Walsh; Erin Wamsley; Martin Paulus; Jennifer C Kanady; Sean P A Drummond
Journal:  J Neurosci       Date:  2013-03-06       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.